<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5479">
  <stage>Registered</stage>
  <submitdate>31/05/2007</submitdate>
  <approvaldate>31/05/2007</approvaldate>
  <nctid>NCT00481117</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability, and Effect of LY2405319 After Multiple Injections in Subjects With Type 2 Diabetes</studytitle>
    <scientifictitle>Safety, Tolerability, PK and PD of LY2405319 After Multiple Subcutaneous Injections in Subjects With Type 2 Diabetes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>I1K-MC-GLUD</secondaryid>
    <secondaryid>11719</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LY2405319
Treatment: drugs - Placebo

Treatment: drugs: LY2405319


Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety labs, ECGs, vital signs, adverse events.</outcome>
      <timepoint>End of dosing period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics (lab samples) and Pharmacokinetics (lab samples)</outcome>
      <timepoint>End of dosing period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Men and women without child bearing capability

          -  Ages 35 to 70 years

          -  Type 2 diabetic subjects, diagnosed for at least 3 months

          -  Average body weight (relative to height)

          -  Willing to be available for the duration of the study</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Significant medical illnesses (except Type 2 diabetes)

          -  Abnormal 12-lead electrocardiogram (ECG )

          -  Current or previous use of insulin for greater than 7 days for control of diabetes

          -  Regular use of drugs of abuse

          -  Excessive alcohol use</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>37</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>India</country>
      <state>Ambawadi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Bangalore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Belgaum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Hyderabaad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Maharashtra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Rabale</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Siddhapudur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Morelia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>George</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study intends to evaluate how safe and well tolerated the LY2405319 compound is when
      given to people for 7 days (in Part 1) and 28 days (in Part 2). This study intends to also
      determine if there is a positive effect on lowering the level of glucose in people with type
      2 diabetes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00481117</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>